Carmignac Gestion Buys New Position in Zoetis Inc. $ZTS

Carmignac Gestion purchased a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, HoldingsChannel reports. The firm purchased 1,575,700 shares of the company’s stock, valued at approximately $113,230,000. Zoetis makes up 1.4% of Carmignac Gestion’s investment portfolio, making the stock its 19th largest holding.

A number of other large investors also recently modified their holdings of the business. Louisiana State Employees Retirement System acquired a new position in Zoetis during the 1st quarter valued at $2,542,000. Wealthfront Advisers LLC grew its position in Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares during the last quarter. Deutsche Bank AG grew its position in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after purchasing an additional 891,921 shares during the last quarter. Pincus Capital Management LP bought a new position in shares of Zoetis during the 4th quarter worth about $2,109,000. Finally, Pacer Advisors Inc. raised its position in shares of Zoetis by 16.7% during the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after buying an additional 23,687 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS traded down $2.25 during mid-day trading on Tuesday, reaching $73.56. The company had a trading volume of 5,656,598 shares, compared to its average volume of 5,703,784. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market capitalization of $30.40 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $152.12. The company’s 50-day moving average is $75.58 and its 200-day moving average is $93.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the firm earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. Piper Sandler lowered their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. TD Cowen cut their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.